drugset / Trial / NCT06511882
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Timeline
- Start
- 2024-11-07
- Primary completion
- 2027-10
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Decitabine | Small molecule | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |